Optimizing clozapine treatment: Part I

Psychopharm Review

Volumn 44, Issue 1, 2009, Pages 1-8

  Phansalkar, Sachin ^a,b   Osser, David N ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Taunton State Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; CYTOCHROME P450 1A2; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

AGRANULOCYTOSIS; ASSAULT; BLOOD CELL COUNT; BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ELECTROCARDIOGRAPHY; HUMAN; HYPONATREMIA; INFORMED CONSENT; LIVER FUNCTION TEST; METABOLIC SYNDROME X; MONOTHERAPY; PHYSICAL EXAMINATION; POLYDIPSIA; RESPIRATION DEPRESSION; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; TREATMENT RESISTANT SCHIZOPHRENIA; URINALYSIS; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 77955603609     PISSN: 19369255     EISSN: None     Source Type: Trade Journal    
DOI: 10.1097/01.idt.0000343379.44905.2f     Document Type: Review

References (45)

1. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophrenia Bull 1997;23(4):663-674.
2. Meltzer HY. Treatment-resistant schizophrenia: the role of clozapine. Current Med Res Opin 1997;14(1):1-20.
3. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-796.
4. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-610.
5. Essock SM, Hargreaves WA, Covell NH, et al. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacology Bull 1996;32(4):683-697.
6. Buchanan RW, Breier A, Kirkpatrick B, et al. Positive and negative symptom response to clozapine in schizophrenic patients with or without the deficit syndrome. Am J Psychiatry 1998;155(6):751-760.
7. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatmentresistant schizophrenia: a review andmeta-analysis of randomized trials. Am J Psychiatry 2001;158(4):518-526.
8. Brunette MF, Drake RE, Xie H, et al. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bull 2006;32(4):637-643. (Pubitemid 44412851)
9. Agid O, Remington G, Kapur S, et al. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol 2007;27(4):369-373.
10. Buckley P, Miller AL, Olsen J, et al.When symptoms persist: clozapine augmentation strategies. Schizophrenia Bull 2001;27(4):615-628.
11. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003;64(1):30-34.
12. Weissman EM. Antipsychotic prescribing practices in the veterans healthcare administration-New York metropolitan region. Schizophrenia Bull 2002;28(1):31-42.
13. Ansari A, Osser DN, Lai LS, et al. Pharmacologic approach to the psychiatric inpatient. In: Ovsiew F, Munich R, eds. Principles of Inpatient Psychiatry. Baltimore, MD: Lippincott Williams & Wilkins, 2008:43-69.
14. Osser DN. The role of guidelines and algorithms for psychopharmacology in 2007. Psychiatric Times 2007;24(4):55-59, 79.
15. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68(11):1751-1762.
16. Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harvard Rev Psychiatry 2001;9(3):89-104.
17. Osser DN, Zarate C. Consultant for the pharmacotherapy of schizophrenia. Psychiatr Ann 1999;29(5):252-267.
18. Osser DN. Consultant for the pharmacotherapy of schizophrenia flowchart. In: Glick ID, Chair. Model Psychopharmacology Curriculum, 5th ed. New York: American Society of Clinical Psychopharmacology, 2008;128-135.
19. McCue RE, Waheed R, Urcuyo L, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006;189:433-440.
20. Suzuki T, Uchida H, Watanabe K, et al. How effective is it to sequentially switch among olanzapine, quetiapine and risperidone?Arandomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology 2007;195(2):285-295.
21. Kahn RS, Fleischhacker WW, Boter H, et al. for the EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008;371(9618):1085-1097.
22. Meltzer H, Alphs L, Green A, et al. Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry 2003;60(1):82-91.
23. Krakowski MI, Czobor P, Citrome L, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006;63(6):622-629.
24. Volavka J, Czobor P, Nolan K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol 2004;24:225-228.
25. Chiles JA, Davidson P, McBride D. Effects of clozapine on use of seclusion and restraint at a state hospital. Hosp Comm Psychiatry 1994;45:269-271.
26. Green AI. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. J Clin Psychiatry 2006;67(suppl 7):31-35.
27. Spears NM, Leadbetter RA, Shutty MS Jr. Clozapine treatment in polydipsia and intermittent hyponatremia. J Clin Psychiatry 1996;57(3):123-128.
28. Henderson DC, Goff DC. Clozapine for polydipsia and hyponatremia in chronic schizophrenics. Biol Psychiatry 1994;36(11):768-770.
29. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992;160:36-43.
30. Patel N, Crismon ML, Miller AL, et al. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy 2005;25(9):1242-1247.
31. Clark NG. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601.
32. Faisal I, Lindenmayer JP, Taintor Z, et al. Clozapinebenzodiazepine interactions. J Clin Psychiatry 1997;58:547-548.
33. WilsonWH. Do anticonvulsants hinder clozapine treatment? Biol Psychiatry 1995;37(2):312-1133
34. Junghan U, AlbersM, Woggon B. Increased risk of hematological side effects in psychiatric patients treated with clozapine and carbamazepine? Pharmacopsychiatry 1993;26:262.
35. VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996;153(12):1579-1584.
36. Schulte P.What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 2003;42(7):607-618.
37. Freudenreich O, Weiner RD, McEvoy JP. Clozapineinduced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry 1997;42(2): 132-137.
38. Lu ML, Lane HY, Chen KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000;61(8):594-599.
39. Oesterheld JR, Sandson NB, Osser DN. Drug-Drug Interaction Software.Available at: www.GeneMedRx.com.
40. HonerWG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-482.
41. Barbui C, SignorettiA, Mule S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment. Schizophr Bull 2008;Apr 23. Epub. doi: 10.1093/ schbul/sbn030.
42. Kane JM, Meltzer HY, Carson JrWH, et al.Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68(2):213-233.
43. Chang JS, Ahn JM, Park HJ, et al.Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebocontrolled trial. J Clin Psychiatry 2008;69(5):720-731.
44. Meltzer HY, BoboWV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment resistant patients with schizophrenia. J Clin Psychiatry 2008;69(2):274-285.
45. Goff DC, Keefe R, Citrome L, et al. Lamotrigine as addon therapy in schizophrenia. J Clin Psychopharmacol 2007;27(6):582-589.